Company Snapshot
Independent ChatGPT assessment · November 9, 2026 · methodology 1.2
Novo Nordisk remains a strong pharmaceutical company with long-term demand for diabetes and obesity treatment. Q3 2026 results show a recovery in volumes and a successful launch of the Wegovy pill. For shareholders, however, the key questions are whether patient growth can outweigh falling net prices and whether high accounting earnings turn into cash after investment. The shares offer interesting potential, but currently require acceptance of business turnaround risk.
| Metric | Position at the analysis date |
|---|---|
| Company | Novo Nordisk A/S, Denmark |
| Assessed instrument | NVO, NYSE ADR, USD; 1 ADR represents 1 class B share |
| Domestic shares | NOVO B, Nasdaq Copenhagen, DKK |
| Reference quote | 40.31 USD, closing price on November 6, 2026, not a live November 9 quote |
| Latest results | Q3 and first nine months of 2026, released November 4, 2026 |
| Business strength | 7.9/10, medium confidence |
| Price attractiveness | 7.0/10 at 40.31 USD, medium confidence |
| Estimated current intrinsic value | 42–54 USD per ADR, working midpoint approximately 48 USD |
| Three-year horizon | Through November 2029; annual 2029 earnings serve as the valuation metric |
Quote: Quiver Quantitative, corroborated by Financial Times. ADR ratio: company information. Methodology: Assessment methodology.
Investment Thesis
Analytical conclusion: long-term demand is very strong, but available reimbursement and competition limit the manufacturer's revenue opportunity. Novo can grow despite a lower market share if the overall treated market expands. Market growth alone does not guarantee earnings-per-share growth.
Eli Lilly remains the largest direct competitor. Efficacy, tolerability, ease of administration, price and reimbursement leave room for several products; leadership in a single study need not determine the commercial winner.
The Business
Novo develops, manufactures and sells medicines. Patients create demand, physicians decide on prescriptions, and access is influenced by insurers, employers, government programs and self-pay channels. The size of the population with obesity therefore cannot be translated directly into paying patient numbers.
| Area | Main offering | Economic significance |
|---|---|---|
| Obesity | Injectable, high-dose and oral Wegovy | Main current growth engine |
| Diabetes | Ozempic, oral offering building on Rybelsus, insulins | Large established base, alongside competitive and pricing pressure |
| Blood and endocrine disorders | For example Sogroya and Norditropin; upcoming denecimig | Smaller base and diversification opportunity |
| Drug development | CagriSema, zenagamtide, amylin and other molecules | Future product renewal and protection against loss of exclusivity |
The business model rests on long-term recurring treatment. This is not a contractually guaranteed subscription: patients can discontinue treatment, switch products or lose reimbursement. The product and development overview is based on the Q3 2026 call.
Cooperation with Hims and Hers
On March 9, 2026, Novo announced an agreement with Hims & Hers to offer approved Ozempic and Wegovy products, including the pill, at Novo self-pay prices. The agreement included changes to the promotion of compounded GLP-1 products and the option for existing patients to transition to approved medicines where clinically appropriate. Novo announcement
News on November 6, 2026: Eli Lilly also announced an agreement with HIMS providing access to Zepbound and Foundayu. HIMS is therefore developing as a distribution platform for multiple manufacturers. Lilly announcement
Analytical conclusion: for Novo this is useful patient access and broader distribution. It is not exclusive protection against Lilly. The published agreements do not allow a reliable estimate of incremental earnings for Novo; the model therefore adds no separate amount solely for HIMS.
Competitive Advantages
Business strength
Business strength: 7.9/10. Assessed on: November 9, 2026. Methodology: 1.2.
| Area | Score | Main evidence |
|---|---|---|
| Competitive advantage | 7.6/10 | Established brands, manufacturing, distribution and a 54% GLP-1 volume share in IO according to the Q3 call; price erosion and loss of exclusivity show the limits of the advantage. |
| Demand durability | 9.0/10 | Chronic conditions and approximately 48 million people on treatment; obesity treatment base growing to 5.6 million according to the Q3 call. Reimbursement constrains realized demand. |
| Management execution | 6.2/10 | Return to growth and expansion of the oral offering; balanced against restructuring, manufacturing and development asset impairments, and the need to restore predictability. |
| Business economics | 8.2/10 | Q3 adjusted operating margin approximately 40% and full-year FCF outlook of 60–70 billion DKK; pricing pressure and investment limit earnings-to-cash conversion. |
| Financial resilience | 8.5/10 | Net debt excluding leases of 79.7 billion DKK at September 30, 2026, below the end of 2025; significant internal cash generation. |
Calculation: (7.6 + 9.0 + 6.2 + 8.2 + 8.5) / 5 = 7.9. Each area has a 20% weight. Sources: call, Q3 presentation, slide 13 and report, appendix 7.
- Brief rationale: Novo has demonstrated scale, manufacturing and research capabilities, and products addressing substantial medical needs. Financial strength supports continued development through a difficult period. Less predictable execution and weaker pricing power constrain the score.
- Main weakness: value concentrated in related metabolic products and the ability to offset falling net prices through volume growth.
- Assessment confidence: medium; scale and profitability are documented, but the business turnaround and success of the new offering are still being established.
- Condition for change: an increase after several quarters of sustainable earnings and cash growth per share; a decrease with continued loss of competitive position, lasting margin deterioration or unsuccessful portfolio renewal.
Growth Drivers
| Product or program | What was announced on the Q3 call | Investment significance and limitations |
|---|---|---|
| Wegovy pill | Around 80% of new US prescriptions within the oral segment according to management; expansion to more than 20 markets in H1 2027 | Broadens access and the patient pool; the quoted share is not a share of all GLP-1 products. |
| Wegovy HD 7.2 mg | Approximately 80% of US high-dose prescriptions come from titration from 2.4 mg | Helps retain patients; mostly not new customers. |
| CagriSema | Preparing for an early 2027 US launch, subject to approval | Potential growth renewal; approval and commercial uptake are not completed outcomes. |
| Zenagamtide | Oral AMAZE 9 in phase III, data expected in 2028 | Next generation combining GLP-1 and amylin biology. |
| Amylin and triple agonists | Further data expected during 2027 | Long-term growth possibility with substantial clinical risk. |
| Denecimig and liver programs | Preparing an expanded offering in hemophilia and MASH | Diversification; no assumption of immediately replacing semaglutide's scale. |
Source: earnings call. Timelines reflect management expectations as of November 4, 2026.
REIMAGINE 5 compared CagriSema 1.0/1.0 mg with tirzepatide 5 mg. Reported weight loss of 12.4% versus 9.1% cannot be generalized into superiority over all tirzepatide doses. Likewise, post-hoc findings in subgroups of women do not replace a prespecified direct comparison. Source T
Analytical conclusion: the base case requires success in part of the portfolio and normal commercial execution. It does not require every new molecule to win or a return to former GLP-1 growth rates.
AI as a research and operating tool
Novo announced partnerships with OpenAI on April 14, 2026, AWS on August 10, 2026 and Anthropic on September 16, 2026. The aims include processing scientific data, identifying drug candidates, supporting research workflows and improving operating efficiency. AWS also mentions a joint development center in London. OpenAI · AWS · Anthropic
Analytical conclusion: the company has data, scientists, clinical and manufacturing capabilities on which it can build AI benefits. Partnerships alone do not demonstrate a higher probability of drug approval. No separate AI premium is added to valuation; any benefit must appear in development productivity, successful products or costs. AI also helps competitors.
Economics & Financial Profile
Amounts are in billions of DKK, except EPS. CER means constant exchange rates.
| Metric | Q3 2026 | 9M 2026 |
|---|---|---|
| Adjusted sales | 79.2 | 227.7 |
| Year-over-year adjusted sales growth at CER | +4% | +2% |
| Adjusted operating profit | 31.7 | 98.0 |
| Adjusted operating margin | 40.1% | 43.0% |
| Reported net profit | 16.7 | 86.3 |
| Adjusted diluted EPS in DKK | 5.79 | 18.60 |
| Free cash flow under the company definition | 28.5 | 83.8 |
Sources: presentation, slide 13 and report, financial overview and appendix 7.
The 27% growth in adjusted operating profit at CER is not the company's new growth rate. It benefited substantially from the comparison with transformation costs in Q3 2025. Full-year adjusted sales and operating profit guidance remains between −2% and +2% at CER. Source T
Reported 9M results were affected by the release of a 26.8 billion DKK 340B provision; this is not recurring medicine sales. Q3 adjusted EPS fell 12% year over year. Adjusted operating profit and adjusted EPS also use different adjustment definitions. Source S
Analytical conclusion: valuation cannot mechanically annualize reported 9M earnings or treat adjusted EBIT growth as EPS growth. Sustainable earnings after pricing changes matter.
The company expects 2026 FCF of 60–70 billion DKK. Investment is expected to decline gradually; CAPEX guidance is approximately 50 billion DKK. 9M FCF cannot be extrapolated linearly to the full year because payment timing affects it. Sources T and V
Net debt excluding leases was 79.7 billion DKK at the end of September versus 95.4 billion DKK at the end of 2025. Source S Financial risk therefore currently centers mainly on returns on investment and development, and less on the need to raise external capital.
Key KPIs
Management reported approximately 48 million people receiving diabetes and obesity treatment, including 5.6 million receiving obesity treatment. According to the company, Novo has a 54% GLP-1 volume share in International Operations. These figures demonstrate scale; they do not represent global value share of the entire obesity market. Source T
The change in direction is positive: adjusted sales at constant exchange rates fell 2% year over year in Q4 2025 and 4% in Q1 2026, before growing 7% in Q2 and 4% in Q3 2026. The company added approximately 2.5 million people on treatment across Q2 and Q3 combined. Source T
Management & Capital Allocation
CEO Mike Doustdar described an ambition for mid-single-digit annual sales growth over 2026–2030. This is a strategic ambition, not confirmed guidance for every year. Luigi La Corte is to succeed Karsten Knudsen as CFO; Knudsen is to remain until year-end for the handover. Source T
The announced 2026 interim dividend was 3.75 DKK per share. This is not the full-year dividend. Future dividends in the model below are analytical estimates. Source D
Risks / Bear Case
| Risk | How it damages shareholder value | What to monitor |
|---|---|---|
| Falling net prices | More patients may not ensure revenue or earnings growth | Net prices, reimbursement mix and margins |
| Competition from Lilly and others | Patient switching, lower prices, higher marketing costs | Shares in comparable segments and commercial uptake of new drugs |
| Reimbursement and the Bridge program | Some growth may depend on access to temporarily supported treatment | Volume outside Bridge and continued reimbursement after 2027 |
| Loss of exclusivity | Generic competition reduces prices and returns on established products | Canada, China and other individual jurisdictions |
| Development failure | Loss of invested capital and future portfolio renewal | Regulatory decisions, full clinical data and discontinued programs |
| Excess or unsuitable manufacturing capacity | Impairments and weaker cash flow amid high investment | CAPEX, factory utilization and earnings-to-cash conversion |
| Currency movements | Impact on DKK results and the USD value of ADRs | USD/DKK, hedging and sales mix |
On the call, management discussed longer-term Ozempic price erosion of approximately 10–15% annually and a Wegovy decline of around 30–35% in that quarter. This is not uniform price guidance for the whole company. It also said that a substantial part of sequential US pill growth relates to Bridge, and that the category excluding its contribution was relatively flat from May to October. Source T
Valuation
ChatGPT produces the calculations and valuation scenarios. Share-price inputs are dated to the analysis; they are not continuously updated market data.
Different outcomes. Different values.
40.31 USD · November 6, 2026
Price Attractiveness
Price Attractiveness: 7.0/10 at 40.31 USD, quote dated November 6, 2026, assessed November 9, 2026. Horizon: three years. Methodology: 1.2.
Shared assumptions
All forecasts below are ChatGPT's own assumptions, not company guidance or market consensus.
- Starting normalized 2026 EPS: 24.0 DKK. It builds on adjusted 9M EPS of 18.60 DKK and assumes a further 5.40 DKK in Q4; it must not be presented as a reported full-year figure. Reported base
- Approximately 4.42 billion shares, including all classes, based on the Q3 diluted average. The count is held constant in every scenario: no additional buyback benefit or significant net dilution.
- A technical exchange rate of 6.70 DKK per USD in every scenario; this is a fixed analytical assumption, not a verified current currency quote.
- EPS includes financing costs and taxes. Debt is therefore not deducted again under the P/E method. Dividends exclude reinvestment and are before taxes, fees and USD/CZK changes.
- Under this normalization, the starting price represents approximately 11.3 times EPS. A low P/E alone does not imply the same cheapness on a cash basis.
Comparable scenarios through November 2029
| Item | Base case | Bear case | Bull case |
|---|---|---|---|
| Business assumptions | Sales grow around 5% annually, new products offset pricing; operating margin around 40–42% | Price erosion, loss of exclusivity and weaker reimbursement; sales stagnate or decline slightly, margin around 33–35% | Faster treatment expansion and success of several products; sales approximately +9% annually, margin around 42–44% |
| Normalized 2029 EPS | 29.40 DKK, approximately 7% annual growth | 19.20 DKK, 20% below the starting base | 33.70 DKK, approximately 12% annual growth |
| Future P/E | 15× | 10× | 18× |
| Price in three years | 65.82 USD | 28.66 USD | 90.54 USD |
| Dividends over three years | 5.40 USD | 4.20 USD | 6.00 USD |
| Total three-year return from 40.31 USD | +76.7% | −18.5% | +139.5% |
| Annualized equivalent of total return | +20.9% | −6.6% | +33.8% |
Price = EPS in DKK × P/E / 6.70. Total return = (price in three years + dividends) / 40.31 − 1. For simplicity, annualization assumes all dividends at the horizon end; it is not the exact internal rate of return on interim payments.
The base multiple of 15× reflects a strong, profitable pharmaceutical company with modest growth, without its former growth premium. The bear multiple of 10× values a permanently weakened position and the risk of further decline. The bull multiple of 18× requires successful growth renewal.
A substantial part of the base return comes from rerating from approximately 11× to 15× earnings. At an unchanged low multiple, the return would be materially lower. The bear case is not the worst possible outcome; serious safety or regulatory problems could cause a larger loss.
Current intrinsic value and cash flow check
Discounting the base target price and three annual dividends of 1.80 USD at a required return of 10% gives 53.9 USD today. This valuation is based on earnings and a future multiple, not an operating cash flow DCF.
A separate indicative DCF uses FCFF, cash after taxes and investment before financing, of 75 / 82 / 90 / 98 / 105 billion DKK in 2027–2031, terminal growth of 2.5%, 4.42 billion shares and the exchange rate above. This is a separate normalized forecast, not a mechanical adoption of the company's FCF metric. It assumes a gradual decline in investment intensity; operating lease payments are included in the forecast.
| WACC | Enterprise value | ADR value after deducting net debt of 79.7 billion DKK |
|---|---|---|
| 8.5% | 1,543 billion DKK | 49.4 USD |
| 9.5% | 1,317 billion DKK | 41.8 USD |
| 10.5% | 1,148 billion DKK | 36.1 USD |
Net debt is deducted only in this enterprise DCF; lease debt is not included a second time. Terminal value represents approximately 74% of enterprise value at a WACC of 9.5%, making the result sensitive to long-term competitiveness.
The working current IV range is 42–54 USD, supported by the central DCF and discounted base case. It is not the range of all possible outcomes; DCF sensitivity extends lower. At 40.31 USD, the discount to the working midpoint of 48 USD is approximately 16%.
Expectations check: with hypothetical starting normalized FCFF of 65 billion DKK, a WACC of 9.5% and terminal growth of 2.5%, a price of 40.31 USD corresponds to approximately 9.4% annual FCFF growth for five years. The market may therefore price in some cash flow recovery even though P/E looks very low.
- Brief rationale: the base case offers a substantial three-year return without requiring exceptional growth. A more cautious cash flow check, however, shows a smaller safety margin than P/E suggests. This corresponds to the lower end of attractive valuation, rather than an exceptional opportunity.
- Main weakness: recovery of cash after investment and the assumed return to 15× earnings.
- Assessment confidence: medium; the quote and starting results are documented, but prices, reimbursement and commercial success of new medicines have a substantial range of outcomes.
- Condition for change: higher attractiveness following a price decline without business deterioration or confirmation of stronger FCF; lower above 55 USD without higher estimates or if normalized earnings power declines.
What Would Change the Assessment?
What would confirm the thesis: obesity treatment growth outside Bridge, a successful CagriSema launch, maintained margins, falling CAPEX with manufacturing reliability preserved, and higher cash per share.
What would undermine the thesis: several quarters of falling normalized EPS despite patient growth, further significant manufacturing investment impairments, lasting reimbursement deterioration or failure of new products to replace price and patent erosion.
Current View
The bands are analytical conditions for monitoring the shares, derived from current assumptions.
| NVO ADR band | Meaning | Necessary condition |
|---|---|---|
| 36–40 USD | First band for gradual entry | Maintained guidance and evidence that higher volumes offset pricing |
| 30–34 USD | Greater safety margin | Price decline without structural damage to key products |
| 42–54 USD | Working current IV range | Further decisions based on execution and cash generation |
| Above 55 USD | Smaller margin under today's model | Requires better results or lower risk |
Thesis History / Updates
| Date | Methodology | Business strength | Price attractiveness | Quote | Reason |
|---|---|---|---|---|---|
| November 9, 2026 | 1.2 | 7.9/10 | 7.0/10 | 40.31 USD, November 6, 2026 close | First analysis after Q3; volume recovery, continuing pricing pressure and valuation checked against cash flow. |
Main sources for both scores:
- T: Novo Nordisk Q3 2026 earnings call, November 4, 2026. Supplied transcript of the November 4, 2026 call covering Q3 and 9M 2026 results. Management statements are distinguished from independent estimates.
- S: Official Q3 and 9M 2026 report filed with the SEC, released November 4, 2026; particularly the financial overview, balance sheet and appendix 7.
- V: Official Q3 2026 presentation, November 4, 2026; particularly the results and outlook slides.
- P and F: Quiver Quantitative and Financial Times, NVO closing quote on November 6, 2026; verified November 9, 2026.
- H and L: Novo agreement with HIMS, March 9, 2026 and Lilly agreement with HIMS, November 6, 2026.
- AI: OpenAI, April 14, 2026, AWS, August 10, 2026, Anthropic, September 16, 2026.
- D and M: ADR and dividend information, verified November 9, 2026, and Assessment methodology, current methodology 1.2.
The analysis is ChatGPT's independent judgment. Intrinsic value estimates and scenarios express assumptions, not certainty of future returns.
Was this analysis useful to you?